TY  - GEN
AU  - Bhusari,Priya
AU  - Vatsa,Rakhee
AU  - Singh,Gurpreet
AU  - Parmar,Madan
AU  - Bal,Amanjit
AU  - Dhawan,Devinder K
AU  - Mittal,Bhagwant R
AU  - Shukla,Jaya
TI  - Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients
SN  - 1097-0215
PY  - 2017///0623
KW  - Adult
KW  - Antineoplastic Agents, Hormonal
KW  - therapeutic use
KW  - Breast Neoplasms
KW  - chemistry
KW  - Combined Modality Therapy
KW  - Feasibility Studies
KW  - Female
KW  - Genes, erbB-2
KW  - Heterocyclic Compounds, 1-Ring
KW  - analysis
KW  - Humans
KW  - Immunoconjugates
KW  - administration & dosage
KW  - Lutetium
KW  - Mastectomy
KW  - Middle Aged
KW  - Molecular Targeted Therapy
KW  - Neoplasm Metastasis
KW  - Neoplasm Proteins
KW  - antagonists & inhibitors
KW  - Pilot Projects
KW  - Radioimmunotherapy
KW  - Radioisotopes
KW  - Receptor, ErbB-2
KW  - Single Photon Emission Computed Tomography Computed Tomography
KW  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
KW  - Tamoxifen
KW  - Tissue Distribution
KW  - Trastuzumab
N1  - Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1002/ijc.30500
ER  -